BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 22210852)

  • 1. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.
    Schipper LG; Vermeer M; Kuper HH; Hoekstra MO; Haagsma CJ; Den Broeder AA; van Riel P; Fransen J; van de Laar MA
    Ann Rheum Dis; 2012 Jun; 71(6):845-50. PubMed ID: 22210852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
    Verschueren P; Esselens G; Westhovens R
    Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.
    Vermeer M; Kievit W; Kuper HH; Braakman-Jansen LM; Bernelot Moens HJ; Zijlstra TR; den Broeder AA; van Riel PL; Fransen J; van de Laar MA
    BMC Musculoskelet Disord; 2013 Dec; 14():350. PubMed ID: 24330489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.
    Fransen J; Moens HB; Speyer I; van Riel PL
    Ann Rheum Dis; 2005 Sep; 64(9):1294-8. PubMed ID: 15829574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
    Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.
    Steunebrink LM; Versteeg GA; Vonkeman HE; Ten Klooster PM; Kuper HH; Zijlstra TR; van Riel PL; van de Laar MA
    Arthritis Res Ther; 2016 Mar; 18():60. PubMed ID: 26956382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
    Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
    J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
    van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
    Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.
    Urata Y; Uesato R; Tanaka D; Nakamura Y; Motomura S
    Ann Rheum Dis; 2012 Apr; 71(4):534-40. PubMed ID: 22021897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study.
    Bakker MF; Jacobs JW; Welsing PM; van der Werf JH; Linn-Rasker SP; van der Veen MJ; Lafeber FP; Bijlsma JW;
    Ann Rheum Dis; 2010 Oct; 69(10):1849-52. PubMed ID: 20511610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort.
    Vermeer M; Kuper HH; Bernelot Moens HJ; Hoekstra M; Posthumus MD; van Riel PL; van de Laar MA
    Arthritis Res Ther; 2012 Nov; 14(6):R254. PubMed ID: 23176083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
    Pincus T
    Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?
    Schipper LG; Fransen J; Barrera P; den Broeder AA; Van Riel PL
    Rheumatology (Oxford); 2009 Oct; 48(10):1247-53. PubMed ID: 19638454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    de Punder YM; Fransen J; Kievit W; Houtman PM; Visser H; van de Laar MA; van Riel PL
    Rheumatology (Oxford); 2012 Sep; 51(9):1610-7. PubMed ID: 22539487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.